November 3, 2025- Baxter International Inc. reported results for the third quarter of 2025.
Third-Quarter 2025 Companywide Financial Results
Baxter notes that continuing operations exclude Baxter’s Kidney Care business, which was acquired by Carlyle in January 2025, and is reported as discontinued operations.
- Worldwide sales from continuing operations in the third quarter totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis.
- U.S. sales from continuing operations in the third quarter totaled approximately $1.54 billion, increasing 3% on a reported basis and declining 1% on an operational basis.
- International sales from continuing operations in the third quarter totaled approximately $1.29 billion, increasing 8% on a reported basis and 5% on an operational basis.
- On a U.S. GAAP basis, net income (loss) from continuing operations totaled ($51) million, or ($0.10) per diluted share in the third quarter.
- On an adjusted basis, net income from continuing operations in the third quarter was $0.69 per diluted share, increasing 41% over the prior year.